For competitive intelligence teams, the key issue is not just current sales
Clinical trials of GLP-1 medications have consistently demonstrated that whilst participants lose considerable weight, a proportion of this weight loss includes lean body mass
In the SURMOUNT-1 trial, those on 15 mg of tirzepatide lost an average of 20.9% over 72 weeks
Engineered antimicrobial peptides for eczema Given the potential to manage the skin microbiome, fight infections, and modulate local immune responses simultaneously, antimicrobial peptides from diverse origins have become one of the most promising alternative solutions for atopic dermatitis management
Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data
While GLP-1RAs demonstrate immunomodulatory potential relevant to SS pathogenesis through their effects on key immune cell populations, direct experimental evidence characterizing their impact on SS-specific immune dysregulation remains strikingly limited